The Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study consists of 85 researchers, including 20 professors and 22 associate professors. The senior staff account for more than 3/4. The Laboratory focuses on innovative drug development for cardiovascular and anti-neurodegenerative diseases, anti-infective and anti-tumor immune-related diseases.
The main research task is evaluating and developing innovative drugs for cardiovascular and cerebrovascular diseases, neurodegenerative diseases, cancer and virus infection by exploring the mechanisms of drugs. We strive to build a domestic first-class drug evaluation center for pharmacodynamics, and provide a technical service platform for enterprises in China. In the past five years, the Laboratory totally obtained more than 100 grants, including National Science and Technology Major Special Project and National Natural Science Foundation of China; and major projects of Beijing Natural Science Foundation. Funds of more than RMB 1 billion were received. The laboratory has published 200 academic articles. It has also made significant achievements in drug development. Three new drugs have entered phase II clinical trial, including anti-cerebral ischemia drug (PHPB), anti-renal dysfunction drug (Nicosamide), and anti-rheumatoid arthritis drug (Chlorobenzopiperidone Hydrochloride). Additionally, FLZ (anti-Parkinson’ disease) and W1302 (anti-Vascular dementia) have applied for clinical trial. More than fifty patents were applied. In addition, the Laboratory has finished more than 100 technical service projects.
The key Laboratory will integrate the multi-disciplinary, highlight and support the key disciplines, and create good conditions for scientific research. We strive to build the key lab into a major pharmacological center for basic research and drug development in China, and provide technical support to Beijing and pharmaceutical R&D institutions and enterprises at home and abroad.
